EA200800766A1 - Ингибиторы pi3k для лечения эндометриоза - Google Patents

Ингибиторы pi3k для лечения эндометриоза

Info

Publication number
EA200800766A1
EA200800766A1 EA200800766A EA200800766A EA200800766A1 EA 200800766 A1 EA200800766 A1 EA 200800766A1 EA 200800766 A EA200800766 A EA 200800766A EA 200800766 A EA200800766 A EA 200800766A EA 200800766 A1 EA200800766 A1 EA 200800766A1
Authority
EA
Eurasian Patent Office
Prior art keywords
endometriosis
treatment
pi3k inhibitors
present
pi3k inhibitor
Prior art date
Application number
EA200800766A
Other languages
English (en)
Inventor
Стефен С. Палмер
Селварадж Натараджа
Original Assignee
Лаборатуар Сероно С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лаборатуар Сероно С.А. filed Critical Лаборатуар Сероно С.А.
Publication of EA200800766A1 publication Critical patent/EA200800766A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к способу лечения и/или профилактики эндометриоза, включающему введение ингибитора PI3K. Ингибитор PI3K может также вводиться в сочетании с супрессором гормонов. Настоящее изобретение дополнительно относится к лечению связанного с эндометриозом бесплодия.
EA200800766A 2005-09-07 2006-08-28 Ингибиторы pi3k для лечения эндометриоза EA200800766A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71464405P 2005-09-07 2005-09-07
EP05109448 2005-10-11
PCT/US2006/033679 WO2007030360A2 (en) 2005-09-07 2006-08-28 P13k inhibitors for the treatment of endometriosis

Publications (1)

Publication Number Publication Date
EA200800766A1 true EA200800766A1 (ru) 2008-06-30

Family

ID=35713975

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200800766A EA200800766A1 (ru) 2005-09-07 2006-08-28 Ингибиторы pi3k для лечения эндометриоза

Country Status (9)

Country Link
US (1) US20080306057A1 (ru)
EP (1) EP1931424A2 (ru)
AU (1) AU2006287765B2 (ru)
BR (1) BRPI0615654A2 (ru)
CA (1) CA2618489A1 (ru)
EA (1) EA200800766A1 (ru)
MX (1) MX2008003189A (ru)
NZ (1) NZ565748A (ru)
WO (1) WO2007030360A2 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101052640B (zh) * 2004-09-03 2011-05-11 默克雪兰诺有限公司 吡啶亚甲基唑烷酮类及其作为磷酸肌醇抑制剂的用途
WO2009026346A1 (en) * 2007-08-20 2009-02-26 Targegen Inc. Thiazolidine compounds, and methods of making and using same
ES2587738T3 (es) 2007-12-21 2016-10-26 Ucb Biopharma Sprl Derivados de quinoxalina y quinolina como inhibidores de quinasa
CN102348798A (zh) 2009-01-16 2012-02-08 麻省理工学院 孤独症谱系障碍的诊断和治疗
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
JP6057896B2 (ja) 2010-08-20 2017-01-11 ノバルティス アーゲー 上皮細胞増殖因子受容体３（ｈｅｒ３）に対する抗体
CN108341873B (zh) 2011-12-05 2022-03-25 诺华股份有限公司 表皮生长因子受体3(her3)的抗体
JP2018512403A (ja) * 2015-03-09 2018-05-17 バイエル ファーマ アクチエンゲゼルシャフト 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン類の使用
CN111315378A (zh) 2017-11-16 2020-06-19 诺华股份有限公司 包含lsz102和瑞博西尼的药物组合
US10695333B2 (en) 2017-12-01 2020-06-30 Novartis Ag Pharmaceutical combination comprising LSZ102 and alpelisib

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799766B2 (en) * 1998-04-08 2010-09-21 Theta Biomedical Consulting & Development Co., Inc. Composition for treating hormonally-dependent cancers
US20040087613A1 (en) * 2002-01-29 2004-05-06 Molmenti Ernesto P. Prevention of adhesions with rapamycin
AU2003255529B2 (en) * 2002-07-10 2008-11-20 Laboratoires Serono Sa Use of compounds for increasing spermatozoa motility
EA011807B1 (ru) * 2002-07-10 2009-06-30 Лаборатуар Сероно Са Азолидинонвинильные производные конденсированного бензола
AU2003295798B2 (en) * 2002-11-21 2009-09-10 Genentech, Inc. Therapy of non-malignant diseases or disorders with anti-ErbB2 antibodies
WO2004056820A1 (en) * 2002-12-20 2004-07-08 Warner-Lambert Company Llc Benzoxazines and derivatives thereof as inhibitors of pi3ks
WO2005011686A1 (en) * 2003-07-28 2005-02-10 Applied Research Systems Ars Holding N.V. 2-imino-4-(thio) oxo-5-poly cyclovinylazolines for use as p13 kinase ihibitors
CA2730540A1 (en) * 2004-05-13 2005-12-01 Vanderbilt University Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.

Also Published As

Publication number Publication date
WO2007030360A2 (en) 2007-03-15
AU2006287765B2 (en) 2011-12-08
CA2618489A1 (en) 2007-03-15
NZ565748A (en) 2011-04-29
WO2007030360A3 (en) 2007-05-31
BRPI0615654A2 (pt) 2011-05-24
AU2006287765A1 (en) 2007-03-15
US20080306057A1 (en) 2008-12-11
EP1931424A2 (en) 2008-06-18
MX2008003189A (es) 2008-03-18

Similar Documents

Publication Publication Date Title
EA200800755A1 (ru) Ikk ингибиторы, предназначенные для лечения эндометриоза
EA200800766A1 (ru) Ингибиторы pi3k для лечения эндометриоза
EA200970932A1 (ru) Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа
EA201690745A1 (ru) Способы лечения и предотвращения болезни "трансплантат против хозяина"
EA200970935A1 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
EA201070740A1 (ru) Способ лечения перелома кости антителами против склеростина
WO2006099261A3 (en) Potent and specific immunoproteasome inhibitors
EA200870029A1 (ru) Способ применения антагонистов il-6 с ингибиторами протеасом
MX366119B (es) Uso de un agente inhibidor de masp-2 para el tratamiento de condiciones renales mediadas por complemento dependiente de la masp-2.
MX2016008201A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
MX2008011633A (es) Aminoquinolonas como inhibidores de gsk-3.
EA200800006A1 (ru) Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i
BRPI0508254A (pt) métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
EA201270184A1 (ru) Лечение расстройств печени ингибиторами pi3k
EA201100609A1 (ru) Способы лечения воспаления
CL2008001782A1 (es) Uso de una composicion que comprende un compuesto derivado de heterociclo para tratar o prevenir la perdida de flujo intestinal; composicion que comprende dicho compusto; y kit que comprende la composicion.
ATE531721T1 (de) Cyanoaminochinolone als gsk-3-inhibitoren
WO2006057997A3 (en) Plasmin-inhibitory therapies
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
EA201001496A1 (ru) Ингибиторы гранулоцитарно-макрофагального колониестимулирующего фактора (gm-csf) и интерлейкина-17 (il-17) для терапии
EA200970164A1 (ru) Ингибиторы каспазы на основе пиридазинонового каркаса
UA96736C2 (ru) Ингибиторы pi3k для лечения эндометриоза
EA200901062A1 (ru) Использование ингибиторов растворимой эпоксидгидролазы для предотвращения и лечения метаболического синдрома и соответствующих расстройств
TW200603792A (en) Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors